135 related articles for article (PubMed ID: 29193025)
21. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
22. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia.
Neale GA; Pui CH; Mahmoud HH; Mirro J; Crist WM; Rivera GK; Goorha RM
Leukemia; 1994 May; 8(5):768-75. PubMed ID: 8182934
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.
Goulden N; Bader P; Van Der Velden V; Moppett J; Schilham M; Masden HO; Krejci O; Kreyenberg H; Lankester A; Révész T; Klingebiel T; Van Dongen J
Br J Haematol; 2003 Jul; 122(1):24-9. PubMed ID: 12823342
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction.
Kwan E; Norris MD; Zhu L; Ferrara D; Marshall GM; Haber M
Br J Haematol; 2000 May; 109(2):430-4. PubMed ID: 10848837
[TBL] [Abstract][Full Text] [Related]
26. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
von Stackelberg A; Seeger K; Henze G; Eckert C
Leukemia; 2004 Oct; 18(10):1727-8; author reply 1728-9. PubMed ID: 15356653
[No Abstract] [Full Text] [Related]
28. Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
Zuna J; Moericke A; Arens M; Koehler R; Panzer-Grümayer R; Bartram CR; Fischer S; Fronkova E; Zaliova M; Schrauder A; Stanulla M; Zimmermann M; Trka J; Stary J; Attarbaschi A; Mann G; Schrappe M; Cario G
Br J Haematol; 2016 Jun; 173(5):742-8. PubMed ID: 26913693
[TBL] [Abstract][Full Text] [Related]
29. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
30. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
[TBL] [Abstract][Full Text] [Related]
31. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
[TBL] [Abstract][Full Text] [Related]
32. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia.
Knechtli CJ; Goulden NJ; Hancock JP; Harris EL; Garland RJ; Jones CG; Grandage VL; Rowbottom AW; Green AF; Clarke E; Lankester AW; Potter MN; Cornish JM; Pamphilon DH; Steward CG; Oakhill A
Br J Haematol; 1998 Aug; 102(3):860-71. PubMed ID: 9722317
[TBL] [Abstract][Full Text] [Related]
34. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.
Coustan-Smith E; Behm FG; Sanchez J; Boyett JM; Hancock ML; Raimondi SC; Rubnitz JE; Rivera GK; Sandlund JT; Pui CH; Campana D
Lancet; 1998 Feb; 351(9102):550-4. PubMed ID: 9492773
[TBL] [Abstract][Full Text] [Related]
35. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
36. The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
Moppett J; Burke GA; Steward CG; Oakhill A; Goulden NJ
J Clin Pathol; 2003 Apr; 56(4):249-53. PubMed ID: 12663634
[TBL] [Abstract][Full Text] [Related]
37. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation.
Sánchez J; Serrano J; Gómez P; Martínez F; Martín C; Madero L; Herrera C; García JM; Casaño J; Torres A
Br J Haematol; 2002 Mar; 116(3):686-94. PubMed ID: 11849234
[TBL] [Abstract][Full Text] [Related]
39. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
Potter MN; Steward CG; Oakhill A
Br J Haematol; 1993 Mar; 83(3):412-8. PubMed ID: 8485046
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
Sekiya Y; Xu Y; Muramatsu H; Okuno Y; Narita A; Suzuki K; Wang X; Kawashima N; Sakaguchi H; Yoshida N; Hama A; Takahashi Y; Kato K; Kojima S
Br J Haematol; 2017 Jan; 176(2):248-257. PubMed ID: 27861730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
